| Attribute |
Value |
| 52 Week Change |
-0.2786463 |
| Address1 |
Novo Alle 1 |
| All Time High |
148.15 |
| All Time Low |
0.08625 |
| Ask |
38.89 |
| Ask Size |
1,100 |
| Average Analyst Rating |
2.7 - Hold |
| Average Daily Volume10 Day |
11,988,030 |
| Average Daily Volume3 Month |
12,815,423 |
| Average Volume |
12,815,423 |
| Average Volume10Days |
11,988,030 |
| Beta |
0.384 |
| Bid |
38.79 |
| Bid Size |
1,300 |
| Book Value |
7.45972 |
| City |
Bagsvaerd |
| Compensation As Of Epoch Date |
1,735,603,200 |
| Country |
Denmark |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
38.83 |
| Current Ratio |
0.873 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,790,726,400 |
| Day High |
39.4 |
| Day Low |
38.67 |
| Debt To Equity |
63.327 |
| Display Name |
Novo Nordisk |
| Dividend Date |
1,787,616,000 |
| Dividend Rate |
1.8 |
| Dividend Yield |
4.58 |
| Earnings Call Timestamp End |
1,785,927,600 |
| Earnings Call Timestamp Start |
1,785,927,600 |
| Earnings Growth |
-0.206 |
| Earnings Quarterly Growth |
-0.208 |
| Earnings Timestamp |
1,793,795,400 |
| Earnings Timestamp End |
1,793,795,400 |
| Earnings Timestamp Start |
1,793,795,400 |
| Ebitda |
173,677,002,752 |
| Ebitda Margins |
0.5272 |
| Enterprise To Ebitda |
1.538 |
| Enterprise To Revenue |
0.811 |
| Enterprise Value |
267,086,528,512 |
| Eps Current Year |
22.38512 |
| Eps Forward |
3.409232 |
| Eps Trailing Twelve Months |
4.09 |
| Esg Populated |
0 |
| Ex Dividend Date |
1,786,924,800 |
| Exchange |
NYQ |
| Exchange Data Delayed By |
20 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
42.8508 |
| Fifty Day Average Change |
-4.0207977 |
| Fifty Day Average Change Percent |
-0.0938325 |
| Fifty Two Week Change Percent |
-27.86463 |
| Fifty Two Week High |
64.16 |
| Fifty Two Week High Change |
-25.330002 |
| Fifty Two Week High Change Percent |
-0.39479426 |
| Fifty Two Week Low |
35.12 |
| Fifty Two Week Low Change |
3.710003 |
| Fifty Two Week Low Change Percent |
0.1056379 |
| Fifty Two Week Range |
35.12 - 64.16 |
| Financial Currency |
DKK |
| First Trade Date Milliseconds |
357,485,400,000 |
| Five Year Avg Dividend Yield |
1.5 |
| Float Shares |
3,173,014,289 |
| Forward Eps |
3.4276135 |
| Forward P E |
11.389663 |
| Free Cashflow |
37,673,250,816 |
| Full Exchange Name |
NYSE |
| Full Time Employees |
66,700 |
| Fullday Change |
-0.5014 |
| Fullday Change Percent |
-1.2784293 |
| Fullday Price |
38.7186 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.81987 |
| Gross Profits |
270,091,993,088 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.000030000001 |
| Held Percent Institutions |
0.09887999 |
| Implied Shares Outstanding |
4,413,110,124 |
| Industry |
Drug Manufacturers - General |
| Industry Disp |
Drug Manufacturers - General |
| Industry Key |
drug-manufacturers-general |
| Ir Website |
http://www.novonordisk.com/investors/default.asp |
| Is Earnings Date Estimate |
0 |
| Language |
en-US |
| Last Dividend Date |
1,786,924,800 |
| Last Dividend Value |
0.579 |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,695,168,000 |
| Last Split Factor |
2:1 |
| Long Business Summary |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. |
| Long Name |
Novo Nordisk A/S |
| Market |
us_market |
| Market Cap |
171,361,075,200 |
| Market State |
POST |
| Max Age |
86,400 |
| Message Board Id |
finmb_323452 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
116,442,996,736 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
170,595,042,854 |
| Number Of Analyst Opinions |
12 |
| Open |
39.33 |
| Operating Cashflow |
131,881,000,960 |
| Operating Margins |
0.42540002 |
| Payout Ratio |
0.431 |
| Peg Ratio |
4.39 |
| Phone |
45 44 44 88 88 |
| Post Market Change |
-0.111400604 |
| Post Market Change Percent |
-0.28689313 |
| Post Market Price |
38.7186 |
| Post Market Time |
1,792,194,794 |
| Previous Close |
39.22 |
| Price Eps Current Year |
1.7346345 |
| Price Hint |
2 |
| Price To Book |
5.2052894 |
| Price To Sales Trailing12 Months |
0.5201729 |
| Profit Margins |
0.35347 |
| Quick Ratio |
0.642 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
hold |
| Recommendation Mean |
2.71429 |
| Region |
US |
| Regular Market Change |
-0.389999 |
| Regular Market Change Percent |
-0.994389 |
| Regular Market Day High |
39.4 |
| Regular Market Day Low |
38.67 |
| Regular Market Day Range |
38.67 - 39.4 |
| Regular Market Open |
39.33 |
| Regular Market Previous Close |
39.22 |
| Regular Market Price |
38.83 |
| Regular Market Time |
1,792,180,802 |
| Regular Market Volume |
9,457,786 |
| Return On Assets |
0.18729 |
| Return On Equity |
0.59815 |
| Revenue Growth |
0.021 |
| Revenue Per Share |
74.186 |
| Sand P52 Week Change |
0.16207206 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
3,338,238,124 |
| Shares Percent Shares Out |
0.0072000003 |
| Shares Short |
31,622,458 |
| Shares Short Previous Month Date |
1,788,134,400 |
| Shares Short Prior Month |
31,648,914 |
| Short Name |
Novo Nordisk A/S |
| Short Percent Of Float |
0.01 |
| Short Ratio |
2.34 |
| Source Interval |
15 |
| Symbol |
NVO |
| Target High Price |
62.040115 |
| Target Low Price |
39.908577 |
| Target Mean Price |
45.809277 |
| Target Median Price |
43.472095 |
| Total Cash |
44,982,001,664 |
| Total Cash Per Share |
10.158 |
| Total Debt |
140,126,994,432 |
| Total Revenue |
329,430,990,848 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
11.7 |
| Trailing Annual Dividend Yield |
0.29831716 |
| Trailing Eps |
4.25 |
| Trailing P E |
9.493888 |
| Trailing Peg Ratio |
4.3209 |
| Triggerable |
1 |
| Two Hundred Day Average |
45.12875 |
| Two Hundred Day Average Change |
-6.298748 |
| Two Hundred Day Average Change Percent |
-0.13957284 |
| Type Disp |
Equity |
| Volume |
9,457,786 |
| Website |
https://www.novonordisk.com |
| Zip |
2,880 |